alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
II 

112TH CONGRESS 

2D SESSION S. 2646 

To suspend temporarily the duty on ascorbic acid encapsulated in cellulose 

acetate butyrate. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Ms. KLOBUCHAR introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To suspend temporarily the duty on ascorbic acid 

encapsulated in cellulose acetate butyrate. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ASCORBIC ACID ENCAPSULATED IN CEL4 LULOSE ACETATE BUTYRATE. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 


rfrederick on DSK6VPTVN1PROD with BILLS
2 

•S 2646 IS

‘‘ 9902.01.00 Ascorbic acid (CAS No. 50– 

81–7) encapsulated in cellulose acetate butyrate (CAS 

No. 9004–36–8) (provided 

for in subheading 

3815.90.50) ........................... Free No change No change On or before 

12/31/2015 ’’. 

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


rfrederick on DSK6VPTVN1PROD with BILLS
* Pursuant to 5TH CIR. R. 47.5, the court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5TH CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

March 7, 2007

Charles R. Fulbruge III

Clerk

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 06-51126

Conference Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

ROBERTO CARLOS MENDEZ-MENDEZ, also known as Roberto

Carretero-Mendez,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Western District of Texas 

USDC No. 3:06-CR-672-ALL

--------------------

Before KING, WIENER, and OWEN, Circuit Judges. 

PER CURIAM:*

Appealing the Judgment in a Criminal Case, Roberto Carlos

Mendez-Mendez raises arguments that are foreclosed by AlmendarezTorres v. United States, 523 U.S. 224, 235 (1998), which held

that 8 U.S.C. § 1326(b)(2) is a penalty provision and not a

separate criminal offense. The Government’s motion for summary

affirmance is GRANTED, and the judgment of the district court is

AFFIRMED.
Schedule of Parties to Indemnification Agreement



 EXHIBIT 10.10.1 
 LIST OF INDEMNITEES 
 Each of the individuals identified below is party to an indemnification agreement with ISTA
Pharmaceuticals, Inc. in the form filed as Exhibit 10.10 to ISTA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007: 
 Vicente Anido, Jr., Ph.D. 
 Lauren P. Silvernail 
 Marvin J. Garrett 
 Kirk McMullin 
 Thomas A. Mitro

 Kathleen McGinley 
 Timothy R. McNamara, Pharm.D. 

Peter Barton Hutt 
 Kathleen D. LaPorte 
 Benjamin F. McGraw III, Pharm.D. 
 Dean J. Mitchell 
 Andrew J. Perlman 
 Wayne I. Roe 
 Richard C. Williams
Cite as 2013 Ark. App. 523

ARKANSAS COURT OF APPEALS

DIVISION II

No. CV-12-688

THOMAS B. QUEEN

APPELLANT

V.

NORTEL NETWORKS; TRAVELERS

PROPERTY & CASUALTY CO.

APPELLEES

OPINION DELIVERED SEPTEMBER 25, 2013

APPEAL FROM THE ARKANSAS

WORKERS’ COMPENSATION

COMMISSION

[NO.F213364]

AFFIRMED

ROBERT J. GLADWIN, Chief Judge

This workers’ compensation case concerns an injury that appellant, Thomas Queen,

suffered on February 18, 2001. The Arkansas Workers’ Compensation Commission

ultimately found on remand, in its April 20, 2012 opinion, that Queen’s injury was

compensable, that Queen’s medical treatment for the period from February 19, 2001,

through January 29, 2003, was compensable, and that temporary total-disability (TTD)

benefits were awarded from February 19, 2001, through July 30, 2002, but that medical

treatment following January 29, 2003, was not reasonably necessary for treatment of his

compensable injury, and also awarded attorney’s fees.1 Appellant contends on appeal that no

substantial evidence supports the denial of additional medical treatment. 

1This is the second time that this case is before this court. In the original appeal, the

Commission found that Queen did not suffer a compensable injury, but this court reversed

and remanded for additional factual findings in Queen v. Nortel Networks, Inc., 2012 Ark. App.

188. 
Cite as 2013 Ark. App. 523

We review a decision of the Workers’ Compensation Commission to determine

whether there is substantial evidence to support it. Crosby v. Eaton Corp., 2012 Ark. App.

565. We review the evidence and all reasonable inferences deducible therefrom in the light

most favorable to the Commission’s findings. Id. It is the Commission’s province to weigh

the evidence and determine what is most credible. Id. The issue on appeal is not whether

we would have reached a different result or whether the evidence would have supported a

contrary conclusion; we will affirm if reasonable minds could reach the Commission’s

conclusion. Id.

It is the Commission’s duty, not ours, to make credibility determinations, to weigh

the evidence, and to resolve conflicts in the medical opinions, evidence, and testimony.

Adams v. Bemis Co., 2010 Ark. App. 859, at 2. Where the Commission has denied a claim

because of the claimant’s failure to meet his or her burden of proof, the substantial-evidence

standard of review requires that we affirm if the Commission’s opinion displays a substantial

basis for the denial of relief. Parson v. Ark. Methodist Hosp., 103 Ark. App. 178, 287 S.W.3d

645 (2008). Because this is the sole issue now before us, and because the Commission’s

opinion adequately explains the decision, we affirm by memorandum opinion. In re

Memorandum Opinions, 16 Ark. App. 301, 700 S.W.2d 63 (1985) (per curiam).

Affirmed.

GLOVER and WHITEAKER, JJ., agree.

H. Oscar Hirby and Robert S. Tschiemer, for appellant.

Phillip Cuffman, for appellee.

2
**Exhibit 23.1** **CONSENT    OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**     We hereby consent to the incorporation by reference in the    Registration Statement on    Form S-3(No. 333-132530)    and    Form S-8(No. 333-122637)    of American Reprographics Company of our report dated    March 1, 2007 relating to the financial statements,    financial statement schedule, management’s assessment of    the effectiveness of internal control over financial reporting    and the effectiveness of internal control over financial    reporting, which appears in this    Form 10-K.     /s/ PricewaterhouseCoopers LLP     Los Angeles, California    March 1, 2007
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2803 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2803

To suspend temporarily the duty on butanamide, N-(2,3-dihydro-2-oxo-1H-
       benzimidazol-5-yl)-2-[2-(2-methoxyphenyl)diazenyl]-3-oxo-.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 7, 2012

   Mr. Kerry introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
To suspend temporarily the duty on butanamide, N-(2,3-dihydro-2-oxo-1H-
       benzimidazol-5-yl)-2-[2-(2-methoxyphenyl)diazenyl]-3-oxo-.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. BUTANAMIDE, N-(2,3-DIHYDRO-2-OXO-1H-BENZIMIDAZOL-5-YL)-2-[2-
              (2-METHOXYPHENYL)DIAZENYL]-3-OXO-.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``     9902.01.00      Butanamide, N-(2,3- Free         No change        No change        On or before 12/  ''.
                        dihydro-2-oxo-1H-                                                  31/2015.......
                        benzimidazol-5-
                        yl)-2-[2-(2-
                        methoxyphenyl)dia
                        zenyl]-3-oxo-
                        (CAS No. 82199-12-
                        0) (provided for
                        in subheading
                        3204.17.60)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
Exhibit
32.2





CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350


AS
ADDED BY


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report
on Form 10-Q of QNB Corp. (the Company) for the period ended March 31, 2010, as
filed with the Securities and Exchange Commission (the Report), I, Bret H.
Krevolin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
§1350, as added by § 906 of the Sarbanes-Oxley Act of 2002, that this periodic
report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in this report
fairly presents, in all material respects, the financial condition and results
of operations of the issuer.





Date:    
      May 17,
      2010
                
                By:
                /s/
      Bret H. KrevolinBret
      H. KrevolinChief
      Financial Officer
II 

112TH CONGRESS 

2D SESSION S. 2859 

To extend the temporary suspension of duty on Pentaerythritol tetrakis[3- 

(dodecylthio)propionate] (CAS No. 29598–76–3). 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. PRYOR introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on Pentaerythritol tetrakis[3-(dodecylthio)propionate] (CAS No. 

29598–76–3). 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. PENTAERYTHRITOL TETRAKIS[3- 

4 (DODECYLTHIO)PROPIONATE] (CAS NO. 29598– 

5 76–3). 

6 (a) IN GENERAL.—Heading 9902.25.06 of the Har7 monized Tariff Schedule of the United States (relating to 

8 Pentaerythritol tetrakis[3-(dodecylthio)propionate] (CAS 

9 No. 29598–76–3)) is amended by striking the date in the 

10 effective period column and inserting ‘‘12/31/2015’’. 


tjames on DSK6SPTVN1PROD with BILLS
2 

•S 2859 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS
**Exhibit31.1**

**CERTIFICATIONSChief Executive Officer**

I, Lori A. Jones, certifythat:

1.  I have reviewed this quarterly report on Form10-QSB of Analytical Surveys, Inc.;

2.  Based on my knowledge, this quarterly reportdoes not contain any untrue statement of a material fact or omit to state amaterial fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading withrespect to the period covered by this quarterly report;

3.  Based on my knowledge, the financialstatements, and other financial information included in this quarterly report,fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presentedin this quarterly report;

4.  The registrant’s other certifying officer andI am responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e)) forthe registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure thatmaterial information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

b)Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this quarterly report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this quarterly report based on such evaluation; and

c)Disclosed in this quarterly report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and

5.  The registrant’s other certifying officer andI have disclosed, based on our most recent evaluation of internal control overfinancial reporting, to the registrant’s auditors and the audit committee ofthe registrant’s board of directors (or persons performing the equivalentfunctions):

a)All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely toadversely affect the registrant’s ability to record, process, summarize andreport financial information; and

b)Any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal control over financialreporting.

Dated:  August 14, 2006

| /s/ LORI  A. JONES        |     |     |
|---------------------------|----------|----------|
| Lori A. Jones             |     |     |
| *Chief Executive Officer* | * * | * * |

 

----
Exhibit 99.4 Aggregate Statement of Principal and Interest Distributions to
            Certificateholders as of December 31,2004

            STRUCTURED ASSET SECURITIES CORPORATION
            MORTGAGE PASS-THROUGH CERTIFICATES
            SERIES 2004-GEL3

      Original         Beginning                                 Ending
Class Balance           Balance   Principal    Interest  Loss    Balance
A    109631000.00  109631000.00  15774496.83  833220.58  0.00   93856503.17
M1    13534000.00   13534000.00        0.00   132193.35  0.00   13534000.00
M2     5752000.00    5752000.00        0.00    66464.36  0.00    5752000.00
B      6090000.00    6090000.00        0.00    83737.50  0.00    6090000.00
P            0.00          0.00        0.00    78080.65  0.00          0.00
Owner Cert.  0.00          0.00        0.00   630958.64  0.00          0.00
R            0.00          0.00        0.00        0.00  0.00          0.00
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2908 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2908

       To extend the temporary suspension of duty on cyprodinil.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2012

  Mr. Conrad introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
       To extend the temporary suspension of duty on cyprodinil.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CYPRODINIL.

    (a) In General.--Heading 9902.02.08 of the Harmonized Tariff 
Schedule of the United States (relating to cyprodinil) is amended by 
striking the date in the effective period column and inserting ``12/31/
2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
EXHIBIT 31.1

                                  CERTIFICATION


I, Sean A. Dobson, certify that:


     1.   I have reviewed this annual report on Form 10-K in respect of the
          USAutos Series 2004-1 Trust (the "Trust");

     2.   Based on my knowledge, the information in this annual report, taken as
          a whole, does not contain any untrue statement of a material fact or
          omit to state a material fact necessary to make the statements made,
          in light of the circumstances under which such statements were made,
          not misleading as of the last day of the period covered by this annual
          report;

     3.   Based on my knowledge, the distribution or servicing information
          required to be provided to the Depositor by the Trustee under the
          pooling and servicing or similar agreement, for inclusion in this
          annual report is included in this report;

     4.   I am responsible for reviewing the activities performed by the
          Depositor and the Trustee under the pooling and servicing or similar
          agreement and based upon my knowledge and the annual compliance review
          required under that agreement, and except as disclosed in this annual
          report, the Depositor and Trustee have each fulfilled its obligations
          under that agreement; and


In giving the certifications above, I have reasonably relied on information
provided to me by the following unaffiliated party: U.S. Bank Trust National
Association, as Trustee.



Date: March 28, 2006


 /s/ Sean A. Dobson
-------------------------
Sean A. Dobson, President
II 

112TH CONGRESS 

2D SESSION S. 2742 

To suspend temporarily the duty on lanthanum oxide. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mr. CASEY introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on lanthanum oxide. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. LANTHANUM OXIDE. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 

‘‘ 9902.01.00 Lanthanum oxide (CAS 

No. 13778–59–1) (provided for in subheading 

2846.90.80) ....................... Free No change No change On or before 

12/31/2015 ’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies to goods entered, or withdrawn from 


rfrederick on DSK6VPTVN1PROD with BILLS
2 

•S 2742 IS

1 warehouse for consumption, on or after the 15th day after 

2 the date of the enactment of this Act. 

Æ 


rfrederick on DSK6VPTVN1PROD with BILLS
II 

112TH CONGRESS 

2D SESSION S. 2867 

To suspend temporarily the duty on 2,5-bis(1,1-dimethylpropyl)-1,4- 

benzenediol. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. PRYOR introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on 2,5-bis(1,1- 

dimethylpropyl)-1,4-benzenediol. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 2,5-BIS(1,1-DIMETHYLPROPYL)-1,4-BENZ4 ENEDIOL. 

5 (a) IN GENERAL.—Subchapter II of chapter 99 of 

6 the Harmonized Tariff Schedule of the United States is 

7 amended by inserting in numerical sequence the following 

8 new heading: 

‘‘ 9902.01.00 2,5-Bis(1,1-dimethylpropyl)- 

1,4-benzenediol (CAS No. 

79–74–3) (provided for in 

subheading 2907.29.90) ........ Free No change No change On or before 

12/31/2015 ’’. 


tjames on DSK6SPTVN1PROD with BILLS
2 

•S 2867 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS
**Exhibit 32.1**

 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANTTO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Annual Report on Form 10-K of The WornickCompany (the “Company”) for the fiscal year ended December 31, 2005 as filedwith the Securities and Exchange Commission on the date hereof (the “Report”),I, Michael M. Thompson, President and Chief Executive Officer of the Company,certify to my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuantto Section 906 of The Sarbanes-Oxley Act of 2002, that:

 

1.                                       TheReport fully complies with the requirements of section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and

 

2.                                       Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
| Date:  March 31, 2006 |   |
|----------------------------|--------|
|                       |   |
|                       |   |
|                       | By:    | /s/ Michael M. Thompson |   |
|                       |   | Michael M. Thompson |
|                       |   | President and Chief Executive Officer |

 

Asigned original of this written statement, or other document authenticating,acknowledging, or otherwise adopting the signature that appears in typed formwithin the electronic version of this written statement, has been provided tothe Company and will be retained by the Company and furnished to the Securitiesand Exchange Commission or its staff upon request.

 

----
Exhibit 31
                                   ----------


                                  CERTIFICATION
                                  -------------

I, Steve Bailey, certify that:

1. I have reviewed this annual report on Form 10-K, and all reports on Form 8-K
containing distribution and servicing reports filed in respect of periods
included in the year covered by this annual report, of CWABS, Inc., Asset-Backed
Certificates Trust 2004-9;

2. Based on my knowledge, the information in these reports, taken as a whole,
does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading as of the
last day of the period covered by this annual report;

3. Based on my knowledge, the distribution or servicing information required to
be provided to the trustee by the master servicer under the pooling and
servicing, or similar, agreement, for inclusion in these reports is included in
these reports;

4. I am responsible for reviewing the activities performed by the master
servicer under the pooling and servicing, or similar, agreement and based upon
my knowledge and the annual compliance review required under that agreement, and
except as disclosed in the reports, the master servicer has fulfilled its
obligations under that agreement; and

5. The reports disclose all significant deficiencies relating to the master
servicer's compliance with the minimum servicing standards based upon the report
provided by an independent public accountant, after conducting a review in
compliance with the Uniform Single Attestation Program for Mortgage Bankers or
similar procedure, as set forth in the pooling and servicing, or similar,
agreement, that is included in these reports.

In giving the certifications above, I have reasonably relied on information
provided to me by the following unaffiliated parties: The Bank of New York, as
Trustee.


Date: March 29, 2005


                                        /s/ Steve Bailey
                                        ----------------
                                        Steve Bailey
                                        Senior Managing Director